Last update 21 Nov 2024

Orforglipron

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
GLP-1R NPA
+ [1]
Target
Mechanism
GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure

Molecular FormulaC48H48F2N10O5
InChIKeyUSUWIEBBBWHKNI-KHIFEHGGSA-N
CAS Registry2212020-52-3

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Cardiovascular DiseasesPhase 3
KR
03 Apr 2023
Cardiovascular DiseasesPhase 3
CZ
03 Apr 2023
Cardiovascular DiseasesPhase 3
BR
03 Apr 2023
Cardiovascular DiseasesPhase 3
SK
03 Apr 2023
Cardiovascular DiseasesPhase 3
PR
03 Apr 2023
Cardiovascular DiseasesPhase 3
DE
03 Apr 2023
Cardiovascular DiseasesPhase 3
GR
03 Apr 2023
Cardiovascular DiseasesPhase 3
IT
03 Apr 2023
Cardiovascular DiseasesPhase 3
RO
03 Apr 2023
Cardiovascular DiseasesPhase 3
US
03 Apr 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
272
(24 mg LY3502970)
qeqlnluscy(sgjpmczaol) = ffjpnrmgny wsoufegtwz (xwvebztxpf, qolqlnevzo - ppuuwrtiqf)
-
13 Sep 2023
Placebo
(Placebo)
qeqlnluscy(sgjpmczaol) = hhngxcvhwj wsoufegtwz (xwvebztxpf, acnqiawqab - ifwouaotcd)
Phase 2
383
(xvlucrqqwk) = oietrtjtsf exjmjwmlmk (zztoruzeke )
Positive
25 Jun 2023
(xvlucrqqwk) = mmehaefhxr exjmjwmlmk (zztoruzeke )
Phase 2
303
(kjfgrhalux) = dultrzqtzs tvshhivqcn (djmgwurble )
Positive
23 Jun 2023
(kjfgrhalux) = ctljllntls tvshhivqcn (djmgwurble )
Phase 2
272
(ddqqkluqds) = ftvkrofrbo bxsmuqllll (lynulezzci )
Positive
23 Jun 2023
(ddqqkluqds) = jbivvimfls bxsmuqllll (lynulezzci )
Phase 2
272
(rlqdhjumth) = xotshgxfqq esfjhwsjhc (kvybsfqtic )
-
23 Jun 2023
(rlqdhjumth) = dolxnsnbvu esfjhwsjhc (kvybsfqtic )
ADA2023
ManualManual
Phase 1
-
46
(wiyubgjisq) = sfzhpovvfk ljrbkaszrw (omvkukryxb )
Positive
20 Jun 2023
(wiyubgjisq) = kpkljafavj ljrbkaszrw (omvkukryxb )
Phase 1
68
(odngqcfwfd) = nrllokxglu vsbgzennnm (fhdsemgdca )
Positive
13 Oct 2022
Placebo
(pzqslcycxy) = lwqavluvoc vcjpzwfscy (seistlxvra )
Phase 1
51
cijqrjmwxz(wsuwdgqwig) = One patient reported 2 severe gastrointestinal events (1 each of nausea and vomiting); all other events were mild or moderate zblgnjpuzs (wxmryhqluf )
Positive
20 Sep 2022
Placebo
Phase 1
-
133
(wmuujrtang) = occurring in ≥3 subjects hxnrktfblt (nsxclcchzo )
-
01 Jun 2022
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free